Key result
Active blood pressure-lowering treatment with perindopril reduced major vascular events by 38% (95% CI, 6 to 59) in patients with atrial fibrillation and prior cerebrovascular disease.
Why the study?
Does perindopril-based blood pressure-lowering reduce major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack?
Population
476 patients with atrial fibrillation and prior stroke or transient ischemic attack, of whom 51% were taking…
Comparison
Active treatment consisting of 2 to 4 mg… vs Matching placebo(s).
Design
RCT, Randomly assigned, Placebo-controlled
Authors
Loading...
Supports perindopril-based BP lowering in AF with prior cerebrovascular disease; extends RCT evidence independent of hypertension or anticoagulation.
RCT (n=476)
Placebo-controlled
Randomly assigned
Does perindopril-based blood pressure-lowering reduce major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack?
Effect estimate: 38% reduction (95% CI 6 to 59)
Routine blood pressure-lowering with a perindopril-based regimen significantly reduces major vascular events in patients with atrial fibrillation and prior cerebrovascular disease, independent of baseline hypertension or anticoagulation use.
Arima et al. (2005) conducted an RCT in Atrial fibrillation and prior stroke or transient ischemic attack (n=476). Perindopril-based blood pressure-lowering vs. Matching placebo was evaluated on Total major vascular events (38% reduction, 95% CI 6 to 59). Active blood pressure-lowering treatment with perindopril reduced major vascular events by 38% (95% CI, 6 to 59) in patients with atrial fibrillation and prior cerebrovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: